BioNTech halts personalized mRNA colorectal-cancer vaccine trial on September 01, 2026 autogene BioNTech BNT122 cevumeran Clinical Trials Colorectal Carcinoma Futility genentech mRNA Vaccine Overall Survival Personalized Phase 2 Roche (company) +
BioNTech–Genentech Halt Personalized Cancer Vaccine Trial After Survival Imbalance on August 31, 2026 autogene BioNTech BNT122 cevumeran Colorectal Carcinoma Data Safety genentech Monitoring Board mRNA cancer Overall Survival Personalized Trial Termination Vaccines +
Aurora’s Personalized CRISPR Ambition Hits Regulatory and Competitive Roadblocks on August 27, 2026 Aurora Therapeutics Beam Therapeutics Clustered Regularly Interspaced Short Palindromic Repeats Gene Modification Infrequent Personalized Phenylketonurias Regulation United States Food and Drug Administration +
Merck–Moderna Cancer-Vaccine Trial Win Sends Stocks Higher on August 20, 2026 intismeran Keytruda melanoma Merck metastasis-free Moderna mRNA cancer neoantigen therapy Personalized Phase 3 trial recurrence-free survival stocks survival Vaccines +
Recent News: ARPA-H Awards Up to $160M for Custom Genetic Medicines on July 13, 2026 ARPA-H Clinical Trials curative medicines Gene Modification genetic medicines GIVE program Hereditary Diseases in vivo Infrequent Personalized Precision - temporal Programs - Publication Format Thrive +
Verily Health Simplifies Medical Jargon with AI-Powered Verily Me App in New Campaign on April 17, 2026 AI health app Health medical jargon Personalized Precision - temporal Recommendation Verily Me Violet AI +
Shaping What's Next in Drug Delivery: 2026 Trends and Innovations on March 20, 2026 autoinjectors Controlled release dosing Drug Delivery Systems Dual-chamber systems Personalized subcutaneous delivery trends qualifier +
Zimmer Biomet Receives U.S. FDA Clearance for Enhanced ROSA Knee Robotic Technology on November 17, 2025 Clearance OptimiZe technology Personalized robotic knee replacement ROSA Knee surgical planning United States Food and Drug Administration Zimmer Biomet +